# Tasigna (nilotinib hydrochloride) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/nilotinib

> Tasigna (nilotinib hydrochloride), sponsored by NOVARTIS AG (NVS): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Tasigna (nilotinib hydrochloride) |
| Codes | AMN107 |
| Sponsor | NOVARTIS AG (NVS) https://sec-api.dev/companies/nvs/catalysts |
| Indications | Chronic Myeloid Leukemia |
| Modality |  |
| FDA designations | priority review |

## Timeline

### September 23, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA022068 SUPPL-35 (Efficacy): submission_status AP, submission_status_date 20210923, review_priority PRIORITY; sponsor_name NOVARTIS; product TASIGNA (NILOTINIB HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022068%22
- openFDA Drugs@FDA: "NDA022068 SUPPL-36 (Efficacy): submission_status AP, submission_status_date 20210923, review_priority PRIORITY; sponsor_name NOVARTIS; product TASIGNA (NILOTINIB HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022068%22

### October 15, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 2. Indication: Chronic Myeloid Leukemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03874858 (A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-15 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT03874858

## Same indication

- [Olverembatinib](https://sec-api.dev/pdufa/olverembatinib) (AAPG)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/nilotinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Tasigna (nilotinib hydrochloride) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/nilotinib

```bibtex
@misc{secapidev_pdufa_nilotinib_20261116,
  title        = {Tasigna (nilotinib hydrochloride) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/nilotinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_nilotinib_20261116","title":"Tasigna (nilotinib hydrochloride) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/nilotinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
